Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Lung · 2024-02 · 202 (1) · 63-72
DOI: 10.1007/s00408-023-00669-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Lung, online erschienen am 24.01.2024. Verfasst von Nobuhiro Kanaji und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenob…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lung Diseases, Interstitial, Lung Neoplasms, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study investigated the safety and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI-induced interstitial lung disease (ILD).
Methods
This multicenter retrospective study collected data from consecutive advanced NSCLC patients who underwent EGFR-TKI re-administration after recovery from EGFR-TKI-induced ILD.
Results
Fifty-eight patients were registered. The grades of initial TKI-induced ILD were grade 1 to 4. TKIs used for re-administration were erlotinib for 15 patients, osimertinib for 15, gefitinib for 14, afatinib for 13 patients, and dacomitinib for 1 patient. ILD recurred in 13 patients (22.4%), comprising 3 patients with grade 1, 6 patients with grade 2, and 4 patients with grade 3. No significant associations were found between ILD recurrence and age, smoking history, performance status, time from initial ILD to TKI re-administration, or concomitant corticosteroid use. However, the incidence of ILD recurrence was high in cases of repeated use of gefitinib or erlotinib or first time use of osimertinib at TKI re-administration. The ILD recurrence rate was lowest in patients treated with first time use of gefitinib (8%) or erlotinib (8%), followed by patients treated with repeated use of osimertinib (9%). The response rate, median progression-free survival by TKI re-administration, and median overall survival were 55%, 9.6 and 84.8 months, respectively.
Conclusion
This study showed that EGFR-TKI re-administration is a feasible and effective treatment for patients who recovered from EGFR-TKI-induced ILD. Our results indicate that re-administration of EGFR-TKI is an important option for long-term prognosis after recovery from EGFR-TKI-induced ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. kanaji.nobuhiro@kagawa…
- Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
- Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
- Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan.
- Department of Respiratory Medicine, Hiroshima Citizens Hospital, Hiroshima, Japan.
ORCID-Profile: Nobuhiro Kanaji
Zitieren
APA
Kanaji, N., Ichihara, E., Tanaka, T., Ninomiya, T., Kozuki, T., Ishikawa, N., Nishii, K., Shoda, H., Yamaguchi, K., Kawakado, K., Toyoda, Y., Inoue, M., Miyatake, N., Watanabe, N., Inoue, T., Mizoguchi, H., Komori, Y., Kojima, K., & Kadowaki, N. (2024). Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005). Lung, 202(1), 63-72. https://doi.org/10.1007/s00408-023-00669-9
Vancouver
Kanaji N, Ichihara E, Tanaka T, Ninomiya T, Kozuki T, Ishikawa N, et al. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005). Lung. 2024;202(1):63-72. doi:10.1007/s00408-023-00669-9
BibTeX
@article{Kanaji2024,
author = {Kanaji, Nobuhiro and Ichihara, Eiki and Tanaka, Takaaki and Ninomiya, Takashi and Kozuki, Toshiyuki and Ishikawa, Nobuhisa and Nishii, Kazuya and Shoda, Hiroyasu and Yamaguchi, Kakuhiro and Kawakado, Keita and Toyoda, Yuko and Inoue, Masaaki and Miyatake, Nobuyuki and Watanabe, Naoki and Inoue, Takuya and Mizoguchi, Hitoshi and Komori, Yuta and Kojima, Kazuki and Kadowaki, Norimitsu},
title = {Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)},
journal = {Lung},
year = {2024},
volume = {202},
number = {1},
pages = {63--72},
doi = {10.1007/s00408-023-00669-9}
}
EUVIMED